<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793077</url>
  </required_header>
  <id_info>
    <org_study_id>BE-11-EGD-04</org_study_id>
    <nct_id>NCT01793077</nct_id>
  </id_info>
  <brief_title>Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients</brief_title>
  <acronym>TREMODI</acronym>
  <official_title>Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veeda Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tremodi is an observational, non-interventional, prospective, open-label, non-comparative
      study that will collect real life data of a treatment with Depo-Eligard® in 3 different
      administrations in male prostate cancer patients.

      Once the examining physician has decided on the therapeutic approach and if the selection
      criteria are fulfilled, he will propose the patient to participate in the study. An informed
      consent form will be collected for all participants in the study.

      There are 2 possible study visits that coincide with a routine consultation, namely visit 1
      (inclusion visit) and visit 2 (end of study visit). On both visits, Adverse Drug Reactions
      (adverse event caused by Depo-Eligard®) are collected and the patient will be asked to
      complete a Quality Of Life questionnaire (EORTC QLQ-C30). At visit 2, the examining physician
      will give a global evaluation of the treatment with Depo-Eligard® and assesses the treatment
      benefit of the patient.

      Testosterone and Prostate Specific Antigen (PSA) blood values are collected during both
      visits, if available.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of tolerability of treatment on a 4 point scale</measure>
    <time_frame>Last Visit (after at least 180 days of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Drug Reactions</measure>
    <time_frame>Day 1 and Last Visit (after at least 180 days of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator satisfaction with treatment</measure>
    <time_frame>Last Visit (after at least 180 days of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient's assessment of treatment benefit</measure>
    <time_frame>Last Visit (after at least 180 days of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life of subjects as measured by EORTC QLQ-C30</measure>
    <time_frame>Day 1 and Last Visit (after at least 180 days of treatment)</time_frame>
    <description>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-C 30 (EORTC-QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of use of dosing schedules of Depo-Eligard® and the reasons for selecting a schedule</measure>
    <time_frame>Day 1 and Last Visit (after at least 180 days of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment</measure>
    <time_frame>Day 1 and Last Visit (after at least 180 days of treatment)</time_frame>
    <description>(1) Changes in PSA and testosterone levels if available, (2) Change in disease symptoms and (3) Objective disease response</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">259</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate Cancer patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-Eligard®</intervention_name>
    <description>Subcutaneous</description>
    <arm_group_label>Prostate Cancer patients</arm_group_label>
    <other_name>Leuprolide Acetate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consultation at urology department
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having been prescribed Depo-Eligard® 7.5 mg - 22.5 mg - 45 mg in accordance
             with the terms of the marketing authorization.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 5</name>
      <address>
        <city>Antwerpen</city>
        <state>Antwerp</state>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 8</name>
      <address>
        <city>Antwerpen</city>
        <state>Antwerp</state>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 9</name>
      <address>
        <city>Antwerpen</city>
        <state>Antwerp</state>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 14</name>
      <address>
        <city>Antwerpen</city>
        <state>Antwerp</state>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4</name>
      <address>
        <city>Antwerpen</city>
        <state>Antwerp</state>
        <zip>2200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 33</name>
      <address>
        <city>Merksem</city>
        <state>Antwerp</state>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 1</name>
      <address>
        <city>Turnhout</city>
        <state>Antwerp</state>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 13</name>
      <address>
        <city>Brussel</city>
        <state>Brussels Capital Region</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 23</name>
      <address>
        <city>Bruxelles</city>
        <state>Brussels Capital Region</state>
        <zip>1030</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 24</name>
      <address>
        <city>Uccle</city>
        <state>Brussels Capital Region</state>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 32</name>
      <address>
        <city>Aalst</city>
        <state>East Flanders</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 34</name>
      <address>
        <city>Dendermonde</city>
        <state>East Flanders</state>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 11</name>
      <address>
        <city>Gent</city>
        <state>East Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 17</name>
      <address>
        <city>Oudenaarde</city>
        <state>East Flanders</state>
        <zip>9700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 18</name>
      <address>
        <city>Tienen</city>
        <state>Flemish Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 39</name>
      <address>
        <city>La Louvière</city>
        <state>Hainaut</state>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 37</name>
      <address>
        <city>Sint Truiden</city>
        <state>Limburg</state>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 26</name>
      <address>
        <city>Lasne Chapelle Saint Lambert</city>
        <state>Walloon Brabant</state>
        <zip>1380</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 21</name>
      <address>
        <city>Ieper</city>
        <state>West Flanders</state>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 20</name>
      <address>
        <city>Izegem</city>
        <state>West Flanders</state>
        <zip>8870</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 25</name>
      <address>
        <city>Kortijk</city>
        <state>West Flanders</state>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 31</name>
      <address>
        <city>Oostende</city>
        <state>West Flanders</state>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 38</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Phase 4</keyword>
  <keyword>Data collection</keyword>
  <keyword>Observational</keyword>
  <keyword>Depo-Eligard</keyword>
  <keyword>Prospective</keyword>
  <keyword>Non-interventional</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

